Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RXRX
STRONG SELLRecursion Pharmaceuticals, Inc. · Healthcare · United States · $1.6B · Avg Vol: $68M/d
COMPANY DESCRIPTION
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company pioneering an industrial-scale drug discovery platform that combines artificial intelligence, automation, and experimental biology to identify and advance novel therapeutic candidates. The company's 'Recursion Operating System' leverages machine learning to rapidly uncover potential treatments for a wide range of diseases, aiming to accelerate the drug discovery process. This unique, tech-driven approach to drug development provides a significant competitive moat, positioning it as an innovator in biotech.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39.7M | 43.9M | 58.5M | 74.3M | 23.2% | 66.4M | 64.4M | 83.3M | 5.9% |
| EPS | -0.50 | -0.71 | -1.69 | -1.44 | — | -1.14 | -0.92 | -0.94 | — |
| Shares | 524.7M | 524.7M | 396.8M | 528.2M | +0.7% | 524.7M | — | — | — |
| Debt | 51.0M | 50.7M | 108.5M | 78.0M | 15.2% | 72.4M | — | — | — |
| Equity | 485.8M | 463.4M | 1.0B | 1.1B | 32.5% | — | — | — | — |
| Op CF | -83.5M | -287.8M | -359.2M | -371.8M | — | -321.0M | — | — | — |
| Inv CF | 193.2M | -10.2M | 260.1M | -16.9M | — | — | — | — | — |
| Fin CF | 154.3M | 140.1M | 304.1M | 521.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RXRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RXRX | Recursion Pharmaceuticals, Inc.(you) | $1.6B | 5 | STRONG SELL |
| GENB | Generate Biomedicines, Inc. | $1.7B | 8 | STRONG SELL |
| MAZE | Maze Therapeutics, Inc. | $1.5B | 10 | STRONG SELL |
| KARD | Kardigan, Inc. | $1.9B | 8 | STRONG SELL |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.2B | 7 | STRONG SELL |
| VRDN | Viridian Therapeutics, Inc. | $2.1B | 3 | STRONG SELL |
| OCUL | Ocular Therapeutix, Inc. | $1.9B | 9 | STRONG SELL |
| AKTS | Aktis Oncology, Inc. | $1.3B | 10 | STRONG SELL |
| AVLN | Avalyn Pharma Inc. | $1.2B | 9 | STRONG SELL |
| SPTX | Seaport Therapeutics, Inc. | $1.1B | 8 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%